PET tracers for clinical imaging of breast cancer

Journal of Oncology

Volumn , Issue , 2012, Pages

  Peñuelas, Iván ^a   Domínguez Prado, Inés ^a   García Velloso, María J ^a   Martí Climent, Josep M ^a   Rodríguez Fraile, MacArena ^a   Caicedo, Carlos ^a   Sánchez Martínez, María ^a   Richter, José A ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; ARGINYLGLYCYLASPARTIC ACID; BROMINE 76; CARBON 11; COPPER 64; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ESTRADIOL; FLUCICLATIDE F 18; FLUORINE 18; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE 6 PHOSPHATE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FRUCTOSE; GALLIUM 68; GLYCOPROTEIN P INHIBITOR; GROWTH FACTOR RECEPTOR; HEXOKINASE 1; IODINE 124; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHORYLCHOLINE; PROGESTERONE RECEPTOR; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB; UNCLASSIFIED DRUG; ZIRCONIUM 89; ZIRCONIUM DERIVATIVE;

ANGIOGENESIS; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG CONJUGATION; DRUG UPTAKE; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR MICROENVIRONMENT;

EID: 84866252964     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/710561     Document Type: Review

References (53)

1. Garami Z., Hascsi Z., Varga J., Dinya T., Tanyi M., Garai I., The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan. European Journal of Surgical Oncology 2012 38 1 31 37 10.1016/j.ejso.2011.09.002
2. Narayanan D., Madsen K. S., Kalinyak J. E., Berg W. A., Interpretation of positron emission mammography and MRI by experienced breast imaging radiologists: performance and observer reproducibility. American Journal of Roentgenology 2011 196 4 971 981 2-s2.0-79957823566 10.2214/AJR.10.5081
3. Groheux D., Giacchetti S., Moretti J. L., Porcher R., Espié M., Lehmann-Che J., de Roquancourt A., Hamy A. S., Cuvier C., Vercellino L., Hindié E., Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging 2011 38 3 426 435 2-s2.0-79953740454 10.1007/s00259-010-1640-9
4. Zornoza G., Gacia-Velloso M. J., Sola J., Regueira F. M., Pina L., Beorlegui C., 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. European Journal of Surgical Oncology 2004 30 1 15 19 2-s2.0-0842323897 10.1016/j.ejso.2003.10.010 (Pubitemid 38180986)
5. Cooper K. L., Meng Y., Harnan S., Ward S. E., Fitzgerald P., Papaioannou D., Wyld L., Ingram C., Wilkinson I. D., Lorenz E., Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation. Health Technology Assessment 2011 15 4 1 134 2-s2.0-79955977734
6. Dunnwald L. K., Doot R. K., Specht J. M., Gralow J. R., Ellis G. K., Livingston R. B., Linden H. M., Gadi V. K., Kurland B. F., Schubert E. K., Muzi M., Mankoff D. A., PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clinical Cancer Research 2011 17 8 2400 2409 2-s2.0-79954611821 10.1158/1078-0432.CCR-10-2649
7. Filippi V., Malamitsi J., Vlachou F., Laspas F., Georgiou E., Prassopoulos V., Andreou J., The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities. Nuclear Medicine Communications 2011 32 2 85 90 2-s2.0-78650935810 10.1097/MNM.0b013e328341c898
8. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation. Cell 2011 144 5 646 674 2-s2.0-79952284127 10.1016/j.cell.2011.02.013
9. Shields A. F., Grierson J. R., Dohmen B. M., Machulla H. J., Stayanoff J. C., Lawhorn-Crews J. M., Obradovich J. E., Muzik O., Mangner T. J., Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Medicine 1998 4 11 1334 1336 2-s2.0-0031790264 10.1038/3337 (Pubitemid 28512118)
10. Been L. B., Elsinga P. H., de Vries J., Cobben D. C. P., Jager P. L., Hoekstra H. J., Suurmeijer A. J. H., Positron emission tomography in patients with breast cancer using 18F-3′-deoxy-3′-fluoro-L-thymidine (18F-FLT)a pilot study. European Journal of Surgical Oncology 2006 32 1 39 43 2-s2.0-30844433923 10.1016/j.ejso.2005.09.011 (Pubitemid 43103986)
11. Vesselle H., Grierson J., Muzi M., Pugsley J. M., Schmidt R. A., Rabinowitz P., Peterson L. M., Vallières E., Wood D. E., In vivo validation of 3′deoxy-3′-[18F]fluorothymidine ([18F]FLT) as a proliferation imaging tracer in humans: correlation of [18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clinical Cancer Research 2002 8 11 3315 3323 2-s2.0-0036847428 (Pubitemid 35340704)
12. Contractor K. B., Kenny L. M., Stebbing J., Rosso L., Ahmad R., Jacob J., 18F]-3′deoxy-3′-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clinical Cancer Research 2011 17 24 7664 7672 10.1158/1078-0432.CCR-11-0783
13. Kenny L., Coombes R. C., Vigushin D. M., Al-Nahhas A., Shousha S., Aboagye E. O., Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy- 3′-[ 18F]fluorothymidine positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging 2007 34 9 1339 1347 2-s2.0-34548173711 10.1007/s00259-007-0379-4 (Pubitemid 47312585)
14. Lubberink M., Direcks W., Emmering J., van Tinteren H., Hoekstra O. S., van der Hoeven J. J., Validity of simplified 3′-deoxy-3′-[(18)F] fluorothymidine uptake measures for monitoring response to chemotherapy in locally advanced breastcancer. Molecular Imaging and Biology. In press 10.1007/s11307-012-0547-1
15. Hussain S. A., Ganesan R., Reynolds G., Gross L., Stevens A., Pastorek J., Murray P. G., Perunovic B., Anwar M. S., Billingham L., James N. D., Spooner D., Poole C. J., Rea D. W., Palmer D. H., Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. British Journal of Cancer 2007 96 1 104 109 2-s2.0-33846211525 10.1038/sj.bjc.6603530 (Pubitemid 46094646)
16. Mikhaylova M., Mori N., Wildes F. B., Walczak P., Gimi B., Bhujwalla Z. M., Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration. Neoplasia 2008 10 4 380 388 2-s2.0-41649115197 10.1593/neo.07854 (Pubitemid 351483578)
17. Valk P. E., Mathis C. A., Prados M. D., Gilbert J. C., Budinger T. F., Hypoxia in human gliomas: demonstration by PET with fluorine-18- fluoromisonidazole. Journal of Nuclear Medicine 1992 33 12 2133 2137 2-s2.0-0026475672
18. Conley S. J., Gheordunescu E., Kakarala P., Newman B., Korkaya H., Heath A. N., Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proceedings of the National Academy of Sciences of the United States of America 2012 109 8 2784 2789 10.1073/pnas.1018866109
19. Laking G., Price P., Radionuclide imaging of perfusion and hypoxia. European Journal of Nuclear Medicine and Molecular Imaging 2010 37 supplement 1 S20 S29 10.1007/s00259-010-1453-x
20. Rajendran J. G., Mankoff D. A., O'Sullivan F., Peterson L. M., Schwartz D. L., Conrad E. U., Spence A. M., Muzi M., Farwell D. G., Krohn K. A., Hypoxia and glucose metabolism in malignant tumors: evaluation by [ 18F] fluoromisonidazole and [18F]]fluorodeoxyglucose positron emission tomography imaging. Clinical Cancer Research 2004 10 7 2245 2252 2-s2.0-11144353536 10.1158/1078-0432.CCR-0688-3 (Pubitemid 38445681)
21. de Molina A. R., Báñez-Coronel M., Gutiérrez R., Rodríguez-González A., Olmeda D., Megías D., Lacal J. C., Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Research 2004 64 18 6732 6739 2-s2.0-4644284916 10.1158/0008-5472.CAN-04-0489 (Pubitemid 39297936)
22. Contractor K. B., Kenny L. M., Stebbing J., Al-Nahhas A., Palmieri C., Sinnett D., Lewis J. S., Hogben K., Osman S., Shousha S., Lowdell C., Coombes R. C., Aboagye E. O., [11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clinical Cancer Research 2009 15 17 5503 5510 2-s2.0-69949091374 10.1158/1078-0432.CCR-09-0666
23. Contractor K. B., Kenny L. M., Stebbing J., Challapalli A., Al-Nahhas A., Palmieri C., Biological basis of [(1)(1)C]choline-positron emission tomography in patients with breast cancer: comparison with [(1)(8)F]fluorothymidine positron emission tomography. Nuclear Medicine Communications 2011 32 11 997 1004 10.1097/MNM.0b013e328349567b
24. Kwee S. A., Coel M. N., Detection of synchronous primary breast and prostate cancer by F-18 fluorocholine PET/CT. Clinical Nuclear Medicine 2010 35 2 128 129 2-s2.0-76149129769 10.1097/RLU.0b013e3181c7c019
25. Mintun M. A., Welch M. J., Siegel B. A., Mathias C. J., Brodack J. W., McGuire A. H., Katzenellenbogen J. A., Breast cancer: PET imaging of estrogen receptors. Radiology 1988 169 1 45 48 2-s2.0-0023811590
26. Sundararajan L., Linden H. M., Link J. M., Krohn K. A., Mankoff D. A., 18F-Fluoroestradiol. Seminars in Nuclear Medicine 2007 37 6 470 476 2-s2.0-34848825649 10.1053/j.semnuclmed.2007.08.003 (Pubitemid 47498260)
27. Hoefnagel L. D. C., van de Vijver M. J., van Slooten H. J., Wesseling P., Wesseling J., Westenend P. J., Bart J., Seldenrijk C. A., Nagtegaal I. D., Oudejans J., van der Valk P., van der Groep P., de Vries E. G. E., van der Wall E., van Diest P. J., Receptor conversion in distant breast cancer metastases. Breast Cancer Research 2010 12 5, article R75 2-s2.0-78650908303 10.1186/bcr2645
28. Kurland B. F., Peterson L. M., Lee J. H., Linden H. M., Schubert E. K., Dunnwald L. K., Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. Journal of Nuclear Medicine 2011 52 10 1541 1549 10.2967/jnumed.111.091439
29. van Kruchten M., Glaudemans A. W., de Vries E. F., Beets-Tan R. G., Schroder C. P., Dierckx R. A., PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. Journal of Nuclear Medicine 2012 53 2 182 190 10.2967/jnumed.111.092734
30. Peterson L. M., Kurland B. F., Link J. M., Schubert E. K., Stekhova S., Linden H. M., Mankoff D. A., Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nuclear Medicine and Biology 2011 38 7 969 978 2-s2.0-79955450464 10.1016/j.nucmedbio.2011.03.002
31. Dehdashti F., Laforest R., Gao F., Aft R. L., Dence C. S., Zhou D., Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16alpha, 17alpha-[(R)-(1′-alpha-furylmethylidene)dioxy]-19- norpregn- 4-ene-3, 20-dione. Journal of Nuclear Medicine 2012 53 3 363 370 10.2967/jnumed.111.098319
32. Kumata K., Ogawa M., Takei M., Fujinaga M., Yoshida Y., Nengaki N., Radiosynthesis of [13N]dantrolene, a positron emission tomography probe for breast cancer resistant protein, using no-carrier-added [13N]ammonia. Bioorganic and Medicinal Chemistry 2012 20 1 305 310 10.1016/j.bmc.2011.10.077
33. Tournier N., Valette H., Peyronneau M. A., Saba W., Goutal S., Kuhnast B., Dollé F., Scherrmann J. M., Cisternino S., Bottlaender M., Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening. Journal of Nuclear Medicine 2011 52 3 415 423 2-s2.0-79952799894 10.2967/jnumed.110.079608
34. Kawamura K., Yamasaki T., Konno F., Yui J., Hatori A., Yanamoto K., Wakizaka H., Ogawa M., Yoshida Y., Nengaki N., Fukumura T., Zhang M. R., Synthesis and in vivo evaluation of 18F-fluoroethyl GF120918 and XR9576 as positron emission tomography probes for assessing the function of drug efflux transporters. Bioorganic and Medicinal Chemistry 2011 19 2 861 870 2-s2.0-78651481940 10.1016/j.bmc.2010.12.004
35. Bauer F., Kuntner C., Bankstahl J. P., Wanek T., Bankstahl M., Stanek J., Mairinger S., Dörner B., Löscher W., Müller M., Erker T., Langer O., Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorganic and Medicinal Chemistry 2010 18 15 5489 5497 2-s2.0-77955419945 10.1016/j.bmc.2010.06.057
36. Dörner B., Kuntner C., Bankstahl J. P., Wanek T., Bankstahl M., Stanek J., Müllauer J., Bauer F., Mairinger S., Löscher W., Miller D. W., Chiba P., Müller M., Erker T., Langer O., Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein. Bioorganic and Medicinal Chemistry 2011 19 7 2190 2198 2-s2.0-79953186881 10.1016/j.bmc.2011. 02.039
37. Kurdziel K. A., Kalen J. D., Hirsch J. I., Wilson J. D., Bear H. D., Logan J., Human dosimetry and preliminary tumor distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT. Journal of Nuclear Medicine 2011 52 9 1339 1345 10.2967/jnumed.111.091587
38. Gasparini G., Brooks P. C., Biganzoli E., Vermeulen P. B., Bonoldi E., Dirix L. Y., Ranieri G., Miceli R., Cheresh D. A., Vascular integrin α (v) β 3: a new prognostic indicator in breast cancer. Clinical Cancer Research 1998 4 11 2625 2634 2-s2.0-0031724191 (Pubitemid 28523488)
39. Beer A. J., Kessler H., Wester H. J., Schwaiger M., PET imaging of integrin α V β 3 expression. Theranostics 2011 1 48 57
40. Beer A. J., Niemeyer M., Carlsen J., Sarbia M., Nahrig J., Watzlowik P., Wester H. J., Harbeck N., Schwaiger M., Patterns of α v β 3 expression in primary and metastatic human breast cancer as shown by 18F-galacto-RGD PET. Journal of Nuclear Medicine 2008 49 2 255 259 2-s2.0-38949212117 10.2967/jnumed.107.045526 (Pubitemid 351225664)
41. Kenny L. M., Al-Nahhas A., Aboagye E. O., Novel PET biomarkers for breast cancer imaging. Nuclear Medicine Communications 2011 32 5 333 335 2-s2.0-79955041164 10.1097/MNM.0b013e32834471ff
42. Tomasi G., Kenny L., Mauri F., Turkheimer F., Aboagye E. O., Quantification of receptor-ligand binding with [(1)(8)F]fluciclatide in metastatic breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging 2011 38 12 2186 2197 10.1007/s00259-011-1907-9
43. Mittra E. S., Goris M. L., Iagaru A. H., Kardan A., Burton L., Berganos R., Chang E., Liu S., Shen B., Chin F. T., Chen X., Gambhir S. S., Pilot pharmacokinetic and dosimetric studies of18F-FPPRGD2: A PET radiopharmaceutical agent for imaging α v β 3 integrin levels. Radiology 2011 260 1 182 191 2-s2.0-79959567221 10.1148/radiol.11101139
44. Buchegger F., Viertl D., Baechler S., Dunet V., Kosinski M., Poitry-Yamate C., 68Ga-NODAGA-RGDyK for α v β 3 integrin PET imaging. Preclinical investigation and dosimetry. Nuklearmedizin 2011 50 6 225 233 10.3413/Nukmed-0416-11-06
45. Verel I., Visser G. W. M., van Dongen G. A., The promise of immuno-PET in radioimmunotherapy. Journal of Nuclear Medicine 2005 46 supplement 1 164S 171S 2-s2.0-14844355681 (Pubitemid 47619032)
46. van Dongen G. A. M. S., Vosjan M. J. W. D., Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biotherapy and Radiopharmaceuticals 2010 25 4 375 385 2-s2.0-77956143094 10.1089/cbr.2010.0812
47. Scott A. M., Wolchok J. D., Old L. J., Antibody therapy of cancer. Nature Reviews Cancer 2012 12 4 278 287 10.1038/nrc3236
48. Walsh G., Biopharmaceutical benchmarks 2010. Nature Biotechnology 2010 28 9 917 924 2-s2.0-77956690413 10.1038/nbt0910-917
49. Kramer-Marek G., Shenoy N., Seidel J., Griffiths G. L., Choyke P., Capala J., 68Ga-DOTA-Affibody molecule for in vivo assessment of HER2/neu expression with PET. European Journal of Nuclear Medicine and Molecular Imaging 2011 38 11 1967 1976 2-s2.0-79959943676 10.1007/s00259-011-1810-4
50. Dijkers E. C., Oude Munnink T. H., Kosterink J. G., Brouwers A. H., Jager P. L., de Jong J. R., van Dongen G. A., Schröder C. P., Lub-de Hooge M. N., de Vries E. G., Biodistribution of 89 Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clinical Pharmacology and Therapeutics 2010 87 5 586 592 2-s2.0-77951474500 10.1038/clpt.2010.12
51. Gaykema S. B., Brouwers A. H., Hovenga S., Lub-de Hooge M. N., de Vries E. G., Schroder C. P., Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer. Journal of Clinical Oncology 2012 30 6 74 75 10.1200/JCO.2011.38.0204
52. McLarty K., Moran M. D., Scollard D. A., Chan C., Sabha N., Mukherjee J., Guha A., McLaurin J., Nitz M., Houle S., Wilson A. A., Reilly R. M., Vasdev N., Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice. Nuclear Medicine and Biology 2011 38 7 953 959 2-s2.0-79955494510 10.1016/j.nucmedbio.2011.02.017
53. Wuest M., Trayner B. J., Grant T. N., Jans H. S., Mercer J. R., Murray D., West F. G., McEwan A. J. B., Wuest F., Cheeseman C. I., Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-d-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer. Nuclear Medicine and Biology 2011 38 4 461 475 2-s2.0-79955478798 10.1016/j.nucmedbio.2010.11.004